No, lenalidomide is NOT administered intravenously
Lenalidomide is administered orally as a capsule, not intravenously 1. This is clearly established in the FDA drug labeling, which describes lenalidomide as an oral medication with absorption occurring through the gastrointestinal tract, with maximum plasma concentrations occurring between 0.5 and 6 hours post-dose 1.
Route of Administration
The FDA labeling explicitly states that lenalidomide is administered orally and can be taken with or without food 1. The drug comes in capsule form at various strengths (5 mg, 10 mg, 15 mg, 20 mg, and 25 mg).
Clinical Context in Multiple Myeloma
In multiple myeloma treatment regimens, lenalidomide is consistently administered orally:
- Standard dosing: 25 mg orally on days 1-21 of a 28-day cycle when combined with dexamethasone 2
- Maintenance therapy: 10-25 mg orally daily (typically starting at 10 mg for the first three cycles, then adjusted to best tolerated dose up to 15 mg) 2
- In combination regimens: When used with carfilzomib (which IS given intravenously) and dexamethasone, lenalidomide remains oral at 25 mg on days 1-21 2
Common Pitfall to Avoid
Do not confuse lenalidomide with other agents in combination regimens. In regimens like VRd (bortezomib-lenalidomide-dexamethasone) or KRd (carfilzomib-lenalidomide-dexamethasone), the proteasome inhibitors (bortezomib, carfilzomib) are given intravenously or subcutaneously, while lenalidomide is always oral 3, 2.
The NCCN guidelines and ASCO guidelines consistently reference lenalidomide as an oral agent in all treatment contexts for multiple myeloma 4, 3.